Our observations support repeat imaging for IAs in patients with ADPKD, positive family history of IA, and negative result of initial screening. Additionally, efforts should be made to develop clinical and/or laboratory risk factors for IAs development in ADPKD patients without family history of IA, which enable to identify patients who should undergo repeat imaging for IAs.

Background Solid organ transplantations lead to improvements in patient survival and patient quality of life, as well as health care system economic benefits. However, over time, health problems can accumulate post-transplantation. Therefore, we hypothesized that in the late post-transplantation period, the costs of patient care increase. Material/Methods We retrospectively calculated costs of patient care in 306 randomly selected kidney transplant recipients who had different follow-up time periods after kidney transplantation (between 1 year and 25 years). Direct costs of inpatient care as well as outpatient care, from the perspective of a transplant center, were considered. Results The mean costs, as well as median costs of post-transplantation care were the highest in the first post-transplantation year. Afterwards, the mean costs and median costs decreased, without an increase in costs of care in the late post-transplantation periods. Conclusions From the perspective of a transplant center, costs of long-term post-kidney transplantation care did not increase in the late period, even as long as 25 years after transplantation. Our results confirmed that kidney transplantation is a modality of renal replacement therapy that can be associated with economic benefits even when considering long-term post-transplantation care.

No abstract

Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent monogenic renal disease with a prevalence of 1:1,000 births and it is the 4th most common cause of dialysis-dependent end-stage renal disease (ESDR). Recent reports suggest an association between APDKD and metabolic derangements, particularly impaired glucose metabolism. Methods: In this cross-sectional study we analyzed data obtained from case records of 189 patients with ADPKD, including kidney transplant recipients, managed in an outpatient department. Results: The mean BMI was 25.4 ± 3.9; 25.25 before and 27.7 after transplan­tation. A fasting glucose level above 100 mg/dL (5.6 mmol/L) was observed in 60 patients (29%) – 27% without transplantation and 41% kidney transplant recipients. Diabetes mellitus was diagnosed in 17 patients (8.9%), including 3 (2.3%) without a history of transplantation and 14 (24.1%) after kidney transplantation (p < 0.01). We observed dyslipidemia in 30% and hyperuricemia in 53% of patients. Conclusion: Demonstrated metabolic abnormalities should be considered in maintenance of ADPKD patients, including kidney transplant recipients.

The dialytic performance was determined by the pre-and post-operative comparison of dialytic venous pressures (DVP) and dialytic flow (DF). The venography was used to confirm the clinical suspect of obstrucion. A predilatation by the use of high-pressure balloon was performed in the obstructions and a pre and post-stenting PTA was performed in all cases. Kaplan-Meier life-table analysis for the treated veins and AVF patency and Cox proportional hazards for time-dependent variables analysis were performed. Results -Over a total of 1613 patients submitted to vascular procedures related to AVF, EVT was performed in 15 (1%) CV cases: 12 (80%) stenoses and 3 (20%) obstructions. Two (13%) patients had a prosthetic and 13 (87%) a proximal AVF. Nine angioplasties, 4 stenting and 2 covered stents were performed in 5 brachiocephalic, 1 subclavian and 9 axillary segments. Technical success was 100% with no complications such as CV rupture or thrombosis. DVP was significantly reduced and DF significantly increased after the procedure (191AE15 mmHg vs 149AE14 mmHg; P¼.001 and 282AE19 ml/min vs 313AE22 ml/min; P.001, respectively). At a mean follow-up of 16 months, the primary patency of the treated veins was 67% and the AVF patency was 100%. Conclusion -EVT is a safe and effective treatment for CV obstruction and stenosis and allows to ameliorate AVF dialytic performance in terms of DVP and DF. References 1. Yadav MK, Sharma M, Lal A, Gupta V, Sharma A, Khandelwal N:Endovascular treatment of central venous obstruction as a complication of prolonged hemodialysis-Preliminary experience in a tertiary care center.